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Introduction
Fluoroquinolone antimicrobial agents have high activity against Gram-negative and
Gram-positive bacteria, and are widely used for the treatment of a variety of bacterial
infections. However, there is continued interest to develop new quinolones with
improved antibacterial activity against Gram-positive organisms or with better
pharmacokinetic profiles (Richard & Gutmann, 1992). OPC-17116 is a new fluorinated
quinolone with 1-cyclopropyl, 5-methyl and 7-methylpiperazino substituents (Yokota,
Arai & Kanda, 1991). Its activity against Enterobacteriaceae and Pseudomonas aerugi-
nosa is comparable to current fluoroquinolones but, as has been observed with other
newly synthesized quinolones, it seems to be more active against Gram-positive
organisms (Imalda et al., 1992).
In this report, we studied the antibacterial activity of OPC-17116 against more than
6000 consecutive, non-fastidious, clinical isolates from six countries and compared its
activity with those of ciprofloxacin and temafloxacin.
Materials and methods
Centres Participating
The six centres participating in the study were Hospital Clinic, University of Barcelona,
Barcelona, Spain; University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA;
University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba, Canada; Escola
Paulista de Medicina, Sao Paulo, Brazil; Kumamoto University Medical School,
Kumamoto, Japan and Kantonsspital Basle, Basel, Switzerland.
Antimicrobial agents
The drugs used in this study were OPC-17116 (Otsuka America Pharmaceuticals,
Rockville, MD, USA); ciprofloxacin (Miles Inc., West Haven, CT, USA); temafloxacin
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(Abbott Pharmaceuticals, North Chicago, IL, USA); oxacillin (Bristol-Myers Squibb,
Wallingford, CT, USA).
Bacterial strains
Each study centre tested at least 1000 consecutive, non-fastidious recent clinical
isolates. Repeat isolates from the same patient were excluded to avoid testing of
multiple copies of the same strain.
MIC determinations
MICs were determined by a broth microdilution method (NCCLS, 1990).
Microdilution trays were prepared by each laboratory except the USA and Brazil
participants who used a common tray lot produced in the USA. The test medium was
cation-adjusted Mueller-Hinton broth. Oxacillin was used at a screening concentration
(2 mg/L) in 2% NaCl broth. The reference strains used in the study were as follows:
Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853, Staphylococcus aureus
ATCC 29213 and Enterococcus faecalis ATCC 29212. The quality control organisms
were tested weekly and results immediately sent by fax to the coordinating laboratory
(University of Iowa Hospitals and Clinics) to assure that the NCCLS guidelines were
followed and to confirm the validity of the data. Each participating centre was also
requested to send the first 20 ciprofloxacin resistant Enterobacteriaceae strains (MIC
> 2 mg/L) detected during the study to the coordinating laboratory for additional
investigation.
Results and discussion
The activities of OPC-17116, ciprofloxacin, and temafloxacin against Gram-negative
and Gram-positive bacteria are given in Tables I and II, respectively. Against members
of the Enterobacteriaceae family, activity of OPC-17116 was equal to or slightly lower
than ciprofloxacin. At < 003-05 mg/L, OPC-17116 inhibited 90% of the isolates
(MIQo) of most species, whereas for Enterobacter, Serratia and Providencia spp.,
OPC-17116 MIQoS ranged from 0-25 to > 4 mg/L. All the strains of other
Enterobacteriaceae tested (11 species) were susceptible to OPC-17116 (MIC*, <
0-12 mg/L). Resistance to ciprofloxacin in Enterobacteriaceae was detected in several
species. Spain (E. coli, 20 strains) and Japan (Providencia rettgeri, eight strains;
Providencia stuartii, three strains; and Serratia marcescens, seven strains) were the
countries with the greatest numbers of resistant isolates, whereas the USA, Canada,
Brazil and Switzerland isolated either no, or no more than five resistant strains. All but
one ciprofloxacin-resistant strain were also resistant to OPC-17116 (MIC > 4 mg/L).
The remaining strain had an OPC-17116 MIC of 4 mg/L which was intrepreted to
indicate the strain belonged to an intermediate category according to the NCCLS
guidelines for other currently available fluoroquinolones (NCCLS, 1990). In this study,
activity of OPC-17116 against members of the family Enterobacteriaceae was similar to
activities reported in previous studies (Imada et ai, 1992; Sader, Envin & Jones, 1992).
However, we found a higher number of ciprofloxacin-resistant bacterial isolates that
were also resistant to OPC-17116. Rates of resistance to fluoroquinolones seem to vary
from country to country. In a recent national survey conducted in the USA (Jones
et al., 1992) resistance to fluoroquinolones was relatively uncommon. In our study, the
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Table I. MICs (mg/L) of OPC-17116, ciprofloxacin and temafloxacin against Gram-negative
clinical isolates
Organism
(no. of isolates)
Citrobacter diversus
(21)
Citrobacter freundii
(86)
Enterobacter
aerogenes (80)
Enterobacter
cloacae (244)
Enterobacter
sakazakii (11)
Enterobacter spp.
(33)
E. co/; (1381)
Klebsiella oxytoca
(97)
Klebsiella
pneumoniae (363)
Morganella
morganni (72)
Proteus mirabilis
(184)
Proteus vulgar is
(22)
/>. rettgeri (17)
Antimicrobial
agent
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
MIC,
sjO-03
s£ 0-015
sSO-03
006
0-03
012
^0-03
012
=£0-03
0-03
0-06
=s£0-03
0-03
012
012
0-06
0-12
scO-03
=g 0-015
=£003
=£ 0-015
0-06
=£0-03
0-03
006
0-12
< 0015
0-25
0-25
0-03
0-25
006
=£0-015
0-25
4
2
2
MIQ,,
=£0-03
=£0-015
0-06
0-5
0-25
1
0-25
0-25
0-5
0-5
0-25
0-5
4
> 2
4
4
>2
>4
0-12
012
0-25
0-06
006
012
012
0-25
0-25
0-25
0-12
1
0-5
006
0-5
0-5
0-06
1
>4
>2
>4
Range
^0-03
=£0-015
=£0-03-0-06
=£0-015->2
=£ 003- > 4
=£ 0-03-1
=£0-015-1
< 0-03-1
=£ 0-03- > 4
<0015-> 2
=£ 0-03- > 4
^ 0-015-> 2
=£ 0-03- > 4
=£ 003- > 4
=£ 0-03- > 4
=£ 003- > 4
^ 0-015- > 2
=£ 003- > 4
=£ 0-03-0-25
=£0-015-0-25
=£ 003-0-5
=£(K>3->4
:£ 003- > 4
s£ 0-03- > 4
=£0-015->2
=£0-03->4
=£ 0-03- > 4
=£0-O15->2
sj 0-03- > 4
=£ 0-03- > 4
^ 0-015- > 2
< 0-03- > 4
=£0-015->2
=£0-O3->4
Susceptibility
888
97
99
94
888
98
96
97
82
82
82
82
79
79
97
97
96
100
100
100
99
97
98
94
94
93
97
97
97
95
95
95
47
47
53
650 F. Marco et at
Table I.—continued
Organism
(no. of isolates)
P. stuartii (13)
Salmonella spp.
(35)
Serratia liquefaciens
(25)
5. marcescens (75)
Serratia spp. (32)
Other Entero-
bacteriaceae* (33)
Aeromonas
hydrophila (11)
A. baumannii (38)
Acinetobacter Iwoffi
(11)
Acinetobacter spp.
(12)
P. aeruginosa (70)
Pseudomonas spp."
X. maltophilia (61)
Antimicrobial
agent
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
MICM
2
05
2
^0015
012
012
012
025
025
012
1
025
012
05
=£0-03
sj 0-015
0-06
006
s£ 0-015
O06
=£003
02
O06
" o 0 6
O06
"O06
^ 0 0 3
05
025
1
006
025
025
025
1
05
mz.
>4
>2
>4
O06
O03
012
4
>2
>4
>4
>2
>4
>4
>2
>4
012
012
05
05
05
1
>4
>2
>4
006
012
012
>4
>2
>4
>4
>2
>4
1
1
2
2
>2
4
Range
< 003- > 4
012-> 4
=£0-03-012
<0-015-O06
< 0-03-O25
< 003- > 4
sS 0-015- > 2
005-> 4
s£ 0.03- > 4
s£O015->2
012-> 4
.*S 003- > 4
sjO015->2
006- > 4
< 003-025
< 0015-1
^ 003-1
< 003-2
^ 0015-1
^ 003-2
< 003- > 4
< 0015- > 2
=£ O03- > 4
< 003-006
< 0015-012
*£ 003-025
< O03- > 4
<O015->2
=S 003- > 4
«S 003- > 4
<O015->2
<O03->4
$O03->4
< 003- > 4
s£ O03- > 4
s£O015->2
< O03- > 4
Susceptibility
62
54
54
g
g
g
80
72
68
80
79
68
73
67
64
100
100
100
g
g
g
84
74
82
8
8
8
83
75
83
74
79
69
95
90
90
90
51
85
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Table I.—continued
Organism Antimicrobial Susceptibility
(no. of isolates) agent MIC^ MIC*, Range (%)
Flavobacterium spp.
(10)
OPC-17116
ciprofloxacin
temafloxacin
Other non-enteric OPC-17116
species* (18) ciprofloxacin
temafloxacin
0-5
2
1
0-5
0-5
0-25
>4
>2
>4
>4
>2
>4
=€ 0-03- > 4
0-5-> 2
0-25-> 4
s£ 003- > 4
<0-015->2
=S 0-03- > 4
70
40
50
78
72
67
"See text.
TaWe II. MICs (mg/L) of OPC-17116, ciprofloxacin and temafloxacin against Gram-positive
clinical isolates
Organism
(no. of isolates)
Enterococcus avium
(18)
E.faecalis (422)
E. faecium (56)
Enterococcus spp.
(176)
Streptococcus spp.
(66)
^-Haemolytic
streptococci (14)
Oxacillin-
susceptible
S. aureus (768)
Oxacillin-resistant
S. aureus (297)
Oxacillin-susceptible
S. epidermidis
(164)
Antimicrobial
agent
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
M I C ,
0-5
1
1
0-5
1
1
2
1
2
012
1
1
012
1
0-5
0-25
0-5
0-5
=$003
0-25
0-12
>4
>2
>4
0-06
025
0-25
MIC*
4
>2
>4
>4
>2
> 4
>4
>2
>4
2
>2
4
0-5
2
1
025
1
1
012
1
025
>4
>2
>4
>4
>2
>4
Range
012-> 4
0-25- > 2
05-> 4
O06->4
O03->2
006-> 4
012-> 2
O06->4
=$O03->4
=$O015->2
=$ O03- > 4
=$003-4
=$0015-2
=$003-2
012-05
05-1
012-1
=$ O03- > 4
=$0-015->2
=$ O03- > 4
=$O03->4
=$0015->2
"o03->2
Susceptibility
83
67
78
70
62
69
61
50
61
90
81
86
98
94
100
888
98
94
97
38
35
37
88
85
87
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Table II.—continued
Organism
(no. of isolates)
Oxacillin-resistant
5. epidermidis
(139)
Staphylococcus
hominis (11)
Oxacillin-
susceptible S.
haemolyticus (13)
Oxacillin-resistant
5. haemolyticus
Staphylococcus
saprophyticus
(15)
Oxacillin-
susceptible
coagulase-
negative
staphylococci
(133)
Oxacillin-resistant
coagulase-
negative
staphylococci
(47)
Staphylococcus
spp." (16)
Other
Gram-positive
species' (18)
Antimicrobial
agent
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
OPC-17116
ciprofloxacin
temafloxacin
MIC,,
012
05
0-25
^ 012
012
006
012
006
>4
>2
>4
012
05
05
=£003
012
012
>4
>2
>4
006
012
012
006
012
05
>4
>2
>4
O06
012
012
>4
>2
>4
>4
>2
>4
012
05
05
012
05
05
>4
>2
>4
025
025
05
025
1
1
Range
< 003- > 4
012-> 2
«: O03- > 4
O06->2
s£ 003-2
< O03- > 4
O06->2
< O03- > 4
006- > 4
05-> 2
012-> 4
s£ O03-0-25
012-1
006-005
^ 003- > 4
<O015->2
=£ O03- > 4
s; O03- > 4
<O015->2
sS O03- > 4
s£ 003- > 4
O03-1
< O03- > 4
sj 003-1
05-1
012-1
Susceptibility
74
64
67
91
73
100
85
85
85
21
14
14
888
95
93
95
46
42
45
94
100
94
888
"See text.
Spanish and Japanese participating centres detected more resistant strains than the
other countries. Results from Spain are in accordance with a previous communication
from this country noting an increase of ciprofloxacin resistance among E. coli isolates
(Rodriguez-Creixems et al., 1991) and it has been suggested that this could be due to
the widespread use of quinolone agents.
Against Acinetobacter baumannii, Xantomonas maltophilia and Flavobaterium spp.
OPC-17116 was the most active fluoroquinolone, but only slightly better to temaflox-
acin. OPC-17116 was, however, less active than ciprofloxacin against P. aeruginosa
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isolates. We also tested OPC-17116 against other species of Pseudomonas spp. (21
strains) and 18 strains of other non-enteric species (Table I), including Alcaligenes
xylosoxidans subsp xylosoxidans (eight strains), Alcaligenes spp. (five strains),
Aeromonas spp. (three strains), Moraxella spp. (one strain) and Pasteurella multocida
(one strain). Our data show that OPC-17116 has a greater spectrum of activity against
the non-enteric Gram-negative bacilli as a group. Also, it had a greater activity against
all species except P. aeruginosa that seems to be slightly more susceptibile to
ciprofloxacin.
OPC-17116 showed greater antibacterial activity against Gram-positive organisms
than ciprofloxacin and temafloxacin. It had a wider spectrum than ciprofloxacin
against 14 of 19 Gram-positive organisms and the same against four organisms. The
average improved spectrum was 6.4% (range 2-18%). When equally potent as cipro-
floxacin, both drugs were usually 100% effective. OPC-17116 inhibited 50% of
Enterococcus spp. isolates at MICs of ^ 0-5 mg/L, except Enterococcus faecium isolates
that were more resistant to all of the fluoroquinolones tested. The MIC,, for
Streptococcus spp., mainly viridans streptococci, was 0-5 mg/L and all /?-haemolytic
streptococci tested were susceptible. OPC-17116 was two- to three-fold more active
than ciprofloxacin against oxacillin-susceptible isolates of S. aureus, Staphylococcus
epidermidis and other coagulase-negative staphylococci. However, when these species
were oxacillin-resistant, the activity of OPC-17116 was only slightly better than
ciprofloxacin. Oxacillin-resistant S. aureus isolates are a serious problem in many
hospitals around the world. Rapid development of resistance to fluoroquinolones in
oxacillin-susceptible and -resistant S. aureus has been reported previously (Blumberg et
al, 1991). Against these isolates, Wakeba & Mitsuhashi (1992) found different percent-
ages of resistance to quinolones suggesting that OPC-17116 showed incomplete cross-
resistance compared with ciprofloxacin. However, in our study, the activity of
OPC-17116 against oxacillin-resistant S. aureus was comparable to or only slightly
better than those of the other quinolones tested.
Oxacillin-resistant Staphylococcus hemolyticus was the most resistant species to all
fluoroquinolones studied. OPC-17116 inhibited 90% of other Staphylococcus spp.
tested at < 0-25 mg/L including Staphylococcus warneri (five strains), Staphyloccoccus
simulans (three strains), Staphylococcus auricularis (three strains), Staphylococcus inter-
medius (two strains), and one strain each of Staphylococcus capitis, Staphylococcus
sciuri and Staphylococcus cohnii. All strains of other Gram-positive species tested such
as Bacillus spp. (11 strains) and Micrococcus spp. (seven strains) were susceptible to the
three quinolones studied.
Finally, OPC-17116 clearly exhibited a wider spectrum against comtemporary patho-
gens than ciprofloxacin in the strains from the six countries. In view of the in-vitro
activity demonstrated in this study, together with results reported elsewhere against
potential respiratory pathogens (Wakebe & Mitsuhashi, 1992) and its pharmacokinetic
properties (Akiyama et al., 1991), OPC-17116 may be an alternative antimicrobial
agent for some serious infections. Accordingly, comparative clinical trials as well as
studies of toxicity and long-term side effects are warranted.
Acknowledgements
We wish to thank the technical support of M. Parera (Microbiology Laboratory,
Hospital Clinic, Barcelona) and S. Anderson for data processing (Iowa ARC
Laboratory).
654 F. Marco et al
References
Akiyama, H., Koike, M., Nii, S., Ohguro, K. & Odomi, M. (1991). OPC-17116, an excellently
tissue-penetrative new quinolone: pharmacokinetic profiles in animals and antibacterial
activities of metabolites. In Program and Abstracts of the Thirty-First Interscience
Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 1477,
p. 345. American Society for Mircobiology, Washington, DC.
Blumberg, H. M., Rimland, D., Carroll, D. J., Terry, P. & Wachsmuth, I. K. (1991). Rapid
development of ciprofloxacin resistance in methicillin-susceptible and -resistant
Staphylococcus aureus. Journal of Infectious Diseases 163, 1279-85.
Imada, T., Miyazaki, S., Nishida, M., Yamaguchi, K. & Goto, S. (1992). In vitro and in vivo
antibacterial activities of a new quinolone, OPC-17116. Antimicrobial Agents and
Chemotherapy 36, 573-9.
Jones, R. N., Reller, L. B., Rosati, L. A., Erwin, M. E., Sanchez, M. L. & the Ofloxacin
Surveillance Group. (1992). Ofloxacin, a new broad-spectrum fluoroquinolone. Results from
a multicenter, national comparative activity surveillance study. Diagnostic Microbiology and
Infectious Diseases 15, 425—34.
National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution
Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically, Second Edition;
Approved Standard M7-A2. NCCLS, Villanova, PA.
Richard, P. & Gutmann, L. (1992). Sparfloxacin and other new fluoroquinolones. Journal of
Antimicrobial Chemotherapy 30, 739-44.
Rodriguez-Creixems, M., Diaz, M. D., Munoz, P., Baraia, J., Cercenado, E. & Bouza, E. (1991).
Emergence of clinical isolates of Escherichia coli resistant to ciprofloxacin. In Program and
Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and
Chemotherapy, Chicago, 1991. Abstract 138, p. 121. American Society for Microbiology,
Washington, DC.
Sader, H. S., Erwin, M. E. & Jones, R. N. (1992). In-vitro activity of OPC-17116 compared to
other broad-spectrum fluoroquinolones. European Journal of Clinical Microbiology and
Infectious Diseases 11, 372-81.
Wakebe, H. & Mitsuhashi, S. (1992). Comparative in-vitro activities of a new quinolone,
OPC-17116, possessing potent activity against Gram-positive bacteria. Antimicrobial Agents
and Chemotherapy 36, 2185-91.
Yokota, T., Arai, K. & Kanda, K. (1991). In vitro activity of OPC-17116, a 4-quinolone newly
synthesized and possessing a methyl moiety at the 5 position. In Program and Abstracts of
the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago,
1991. Abstract 1462, p. 342. American Society for Microbiology, Washington, DC.
(Received 22 March 1993; revised version accepted 1 November 1993)
